文献速递前列腺癌

68Ga-PSMA-11 PET/CT与68Ga-PSMA-11 PET/MRI在前列腺癌生化复发检测中的头对头比较:头对头比较研究的总结

Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-08-05

本荟萃分析评估68Ga-PSMA-11 PET/CT与PET/MRI对前列腺癌生化复发的诊断效能,检索PubMed和Embase至2022年2月,纳入5项头对头比较研究共219例患者。两种显像方式总体检出率无显著差异(P=0.82),局部复发、淋巴结转移和骨转移检出率亦无显著差异。作者认为两者表现似乎相当,但结果来自小样本研究,需进一步开展更大规模研究。

要点

  • 5项头对头研究共219例患者,比较68Ga-PSMA-11 PET/CT与PET/MRI对生化复发的检出。
  • 总体检出率PET/CT为0.89(95%CI 0.65-1.00),PET/MRI为0.92(95%CI 0.77-1.00),差异无统计学意义(P=0.82)。
  • 局部复发、淋巴结转移和骨转移检出率在两种显像间均无显著差异(P分别为0.54、1.00、0.82)。

核心结论

  • 68Ga-PSMA-11 PET/CT与68Ga-PSMA-11 PET/MRI在前列腺癌生化复发检测中似乎表现相当。
  • 荟萃分析结果来自小样本研究,需进一步开展更大规模研究。

研究设计与样本

  • 荟萃分析,检索PubMed和Embase截至2022年2月,纳入评估68Ga-PSMA-11 PET/CT与PET/MRI头对头比较的原始研究。
  • 共纳入5项研究、219例前列腺癌生化复发患者,采用QUADAS-2工具评估研究质量。

主要发现

  • 总体检出率:68Ga-PSMA-11 PET/CT为0.89(95%CI 0.65-1.00),68Ga-PSMA-11 PET/MRI为0.92(95%CI 0.77-1.00)。
  • 局部复发检出率:PET/CT为0.20(95%CI 0.05-0.41),PET/MRI为0.29(95%CI 0.10-0.53)。
  • 淋巴结转移检出率:PET/CT为0.51(95%CI 0.33-0.69),PET/MRI为0.52(95%CI 0.44-0.61)。
  • 骨转移检出率:PET/CT为0.18(95%CI 0.07-0.33),PET/MRI为0.20(95%CI 0.09-0.35)。
  • 两种显像方式总体检出率无显著差异(P=0.82);局部复发、淋巴结转移和骨转移检出率亦无显著差异(P分别为0.54、1.00、0.82)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 荟萃分析结果来自小样本研究。
  • 需进一步开展更大规模研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our meta-analysis aimed to evaluate the diagnostic performance of 68Ga-PSMA-11 PET/CT vs. 68Ga-PSMA-11 PET/MRI for biochemical recurrence of prostate cancer. METHODS: We searched for relevant articles in PubMed and Embase until February 2022. Studies evaluating head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in men with prostate cancer biochemical recurrence were included. The quality of each study was assessed using the Quality Assessment of Diagnostic Performance Studies-2 (QUADAS-2) tool. RESULTS: A total of 5 studies with 219 patients were included in the analysis. The pooled overall detection rates of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in detecting recurrent PCa after definitive treatment were 0.89 (95% CI: 0.65-1.00), 0.92 (95% CI: 0.77-1.00), while the detection rates were 0.20 (95% CI: 0.05-0.41) and 0.29 (95% CI: 0.10-0.53) in local recurrence, 0.51 (95% CI: 0.33-0.69) and 0.52 (95% CI: 0.44-0.61) in lymph node metastasis, 0.18 (95% CI: 0.07-0.33) and 0.20 (95% CI: 0.09-0.35) in bone metastasis. There was no significant difference between the two imaging modalities in the overall detection rate (P = 0.82). In addition, detection rates were also not significantly different in local recurrence, lymph node metastasis, or bone metastasis (P = 0.54, 1.00, 0.82). CONCLUSIONS: 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI seem to have equivalent performance in detecting biochemical recurrence in prostate cancer. However, the results of the meta-analysis were drawn from studies with small samples. Further larger studies in this setting are warranted.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Huo H, Shen S, He D, et al. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies. Prostate Cancer Prostatic Dis. 2022. PMID: 35931759. doi:10.1038/s41391-022-00581-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。